

BIBLIOGRAFÍA CONSULTADA:

MÓDULO 2- FÁRMACOS UTILIZADOS EN LA INDUCCIÓN DEL ABORTO FARMACOLÓGICO

“FARMACOCINÉTICA Y FARMACODINAMIA DE LA MIFEPRISTONA”

DR. MODESTO REY NOVOA

Deraedt R, Bonnat C, Busigny M, et al. Pharmacokinetics of RU 486. In: Baulieu E-E, Segal S, editors. The antiprogestin steroid RU 486 and human fertility control. New York: Plenum Press, 1985. p. 103–22.

Heikinheimo O, Tevilin M, Shoupe D, Croxatto H, Lahteenmäki P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. *Contraception* 1986;34:613–23.

Heikinheimo O, Lahteenmaki PL, Koivunen E, Shoupe D, Croxatto H, Luukkainen T, et al. Metabolism and serum binding of RU 486 in women after various single doses. *Hum Reprod* 1987;2:379–85.

Heikinheimo O, Croxatto H, Salvatierra A, Chang C, Luukkainen T, Lahteenmäki P. Intravaginal administration of RU486 in humans and rats: inadequate absorption in humans. *Hum Reprod* 1987;2:645

World Health Organization. Termination of pregnancy with reduced doses of mifepristone. *BMJ* 1993;307:532–537

Kekkonen R, Heikinheimo O, Mandelin E, Lahteenmäki P. Pharmacokinetics of mifepristone after low oral doses. *Contraception* 1996; 54:229–34

Creinin M, Pymar H, Schwartz J. Mifepristone 100 mg abortion regimens. *Obstet Gynecol* 2001;98:434–9.

Heikinheimo O. Pharmacokinetics of the antiprogestin RU486 in women during multiple dose administration. *J Steroid Biochem* 1989; 32:21–5.

Fiala C, Gemzel-D World Health Organization. Task force on post-ovulatory methods of fertility regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomized trial. *Br J Obstet Gynecol* 2000;107:524–30.

Danielsson K (2006). «Review of medical abortion using mifepristone in combination with a prostaglandin analogue». *Contraception* 74 (1):6686. doi:10.1016/j.contraception.2006.03.018. PMID 16781264.

Heikinheimo O, Kekkonen R, Lahteenmaki P (2003). «The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action». *Contraception* 68 (6): 421-6.

Fernández-Valdivia R, Mukherjee A, Mulac-Jericevic B, Conneely OM, DeMayo FJ, Amato P, et al. Revealing progesterone's role in uterine and mammary gland biology: insights from the mouse. *Semin Reprod Med* 2005;23:22-37

SUAREZ-CALDERON, Diana Marcela and DIAZ-YAMAL, Ivonne. Antagonistas de receptores de progesterona (PRA) y moduladores selectivos de receptores de progesterona (SPRM): aplicaciones en ginecología y obstetricia. *Rev Colomb Obstet Ginecol* [online]. 2008, vol.59, n.1, pp.31-37.

Ficha técnica. Ministerio de Sanidad, Política Social e Igualdad. Revisión 2015.